[HTML][HTML] The use of neuroimaging techniques in the early and differential diagnosis of dementia
L Chouliaras, JT O'Brien - Molecular Psychiatry, 2023 - nature.com
Dementia is a leading cause of disability and death worldwide. At present there is no
disease modifying treatment for any of the most common types of dementia such as …
disease modifying treatment for any of the most common types of dementia such as …
Imaging the substantia nigra in Parkinson disease and other Parkinsonian syndromes
Parkinson disease is characterized by dopaminergic cell loss in the substantia nigra of the
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …
midbrain. There are various imaging markers for Parkinson disease. Recent advances in …
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear …
Objectives This longitudinal study compared emerging plasma biomarkers for
neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy …
neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy …
[HTML][HTML] Neuroimaging advances in Parkinson's disease and atypical Parkinsonian syndromes
Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …
heterogeneous neurodegenerative diseases that share clinical characteristic of …
[HTML][HTML] Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease
The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded
beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is …
beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is …
[HTML][HTML] Elucidating distinct molecular signatures of Lewy body dementias
Dementia with Lewy bodies and Parkinson's disease dementia are common
neurodegenerative diseases that share similar neuropathological profiles and spectra of …
neurodegenerative diseases that share similar neuropathological profiles and spectra of …
[HTML][HTML] Imaging mild cognitive impairment and dementia in Parkinson's disease
S Sasikumar, AP Strafella - Frontiers in neurology, 2020 - frontiersin.org
Cognitive dysfunction is a significant non-motor feature of Parkinson's disease, with the risk
of dementia increasing with prolonged disease duration. Multiple cognitive domains are …
of dementia increasing with prolonged disease duration. Multiple cognitive domains are …
Neuropsychological impairments and their cognitive architecture in mild cognitive impairment (MCI) with Lewy bodies and MCI-Alzheimer's disease
J Ciafone, A Thomas, R Durcan… - Journal of the …, 2022 - cambridge.org
Objective: The present study aimed to clarify the neuropsychological profile of the emergent
diagnostic category of Mild Cognitive Impairment with Lewy bodies (MCI-LB) and determine …
diagnostic category of Mild Cognitive Impairment with Lewy bodies (MCI-LB) and determine …
FDG‐PET markers of heterogeneity and different risk of progression in amnestic MCI
SP Caminiti, S De Francesco, G Tondo… - Alzheimer's & …, 2024 - Wiley Online Library
INTRODUCTION Amnestic mild cognitive impairment (aMCI) is emerging as a
heterogeneous condition. METHODS We looked at a cohort of N= 207 aMCI subjects, with …
heterogeneous condition. METHODS We looked at a cohort of N= 207 aMCI subjects, with …
[HTML][HTML] Biological Diagnosis of Alzheimer's Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?
B Souchet, A Michaïl, B Billoir, J Braudeau - International Journal of …, 2023 - mdpi.com
Alzheimer's disease (AD) was first characterized by Dr. Alois Alzheimer in 1906 by studying
a demented patient and discovering cerebral amyloid plaques and neurofibrillary tangles …
a demented patient and discovering cerebral amyloid plaques and neurofibrillary tangles …